Axsome Therapeutics, Inc.
AXSM
Rang in Aktien
#2358
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to... Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Aktienkurs
$157.20
Zuletzt synchronisiert: 2026-10-21
Marktkapitalisierung
$8.23B
Veränderung (1 Tag)
-1.49%
Veränderung (1 Jahr)
21.18%
Land
US
Handel Axsome Therapeutics, Inc. (AXSM)
Kategorie
Healthcare
Kursverlauf für Axsome Therapeutics, Inc. (AXSM)
Höchster Schlusskurs: $166.68 am 2026-10-01
Niedrigster Schlusskurs: $8.99 am 2015-11-01
Niedrigster Schlusskurs: $8.99 am 2015-11-01
Kursverlauf der Aktie von Axsome Therapeutics, Inc. von 2015 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | 25.48% |
| 2025 | 62.10% |
| 2024 | 26.95% |
| 2023 | -4.24% |
| 2022 | 118.74% |
| 2021 | -56.59% |
| 2020 | 11.03% |
| 2019 | 2,538.67% |
| 2018 | -44.64% |
| 2017 | -23.67% |
| 2016 | -25.67% |
| 2015 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $761.12 | 8.18% |
CH
|
